These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1971660)

  • 1. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.
    Wiklund O; Angelin B; Olofsson SO; Eriksson M; Fager G; Berglund L; Bondjers G
    Lancet; 1990 Jun; 335(8702):1360-3. PubMed ID: 1971660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
    Wiklund O; Angelin B; Fager G; Eriksson M; Olofsson SO; Berglund L; Lindén T; Sjöberg A; Bondjers G
    J Intern Med; 1990 Sep; 228(3):241-7. PubMed ID: 2119417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational therapy of familial hypercholesterolemia.
    Reynolds GA
    Circulation; 1989 May; 79(5):1146-8. PubMed ID: 2496938
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W; Bimmermann A; Schleicher J
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment.
    Jay RH; Rampling MW; Betteridge DJ
    Atherosclerosis; 1990 Dec; 85(2-3):249-56. PubMed ID: 2129320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.
    Kume N; Kita T; Mikami A; Yokode M; Ishii K; Nagano Y; Kawai C
    Circulation; 1989 May; 79(5):1084-90. PubMed ID: 2496935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
    Athyros VG; Papageorgiou AA; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2001; 17(4):267-72. PubMed ID: 11922400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy.
    Berglund L; Wiklund O; Eggertsen G; Olofsson SO; Eriksson M; Lindén T; Bondjers G; Angelin B
    J Intern Med; 1993 Feb; 233(2):173-8. PubMed ID: 8433078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
    Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
    Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
    Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
    Betteridge DJ; Bhatnager D; Bing RF; Durrington PN; Evans GR; Flax H; Jay RH; Lewis-Barned N; Mann J; Matthews DR
    BMJ; 1992 May; 304(6838):1335-8. PubMed ID: 1611329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.
    Sun XM; Patel DD; Knight BL; Soutar AK
    Atherosclerosis; 1998 Jan; 136(1):175-85. PubMed ID: 9544745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
    QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.
    Hoogerbrugge N; Mol MJ; Van Dormaal JJ; Rustemeijer C; Muls E; Stalenhoef AF; Birkenhäger JC
    J Intern Med; 1990 Sep; 228(3):261-6. PubMed ID: 2119419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
    Mabuchi H; Kamon N; Fujita H; Michishita I; Takeda M; Kajinami K; Itoh H; Wakasugi T; Takeda R
    Metabolism; 1987 May; 36(5):475-9. PubMed ID: 3106756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein(a) and ischaemic heart disease.
    Jones AF; Lemon M; Bain SC; Walker MR
    Lancet; 1990 Sep; 336(8718):813-4. PubMed ID: 1976174
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.
    Barrow SE; Stratton PD; Benjamin N; Brassfield T; Ritter JM
    Br J Clin Pharmacol; 1991 Jul; 32(1):127-9. PubMed ID: 1909541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.